SCHEMBL712433

SCHEMBL712433

O=C1c2ccccc2C(=O)c2c1ccc1nc(CN3CCC4(CC3)OCCO4)[nH]c21

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.45
TERT O14746 1/20 0.42
HPGD P15428 3/20 0.39
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
HSD17B10 Q99714 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
PARP1 P09874 2/20 0.36
ADORA2A P29274 1/20 0.36
HIF1A Q16665 2/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713005 0.86 HPGD (0.54) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL713856 0.84 HTT (0.52) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL713735 0.84 HTT (0.52) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL712820 0.82 TERT (0.45) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL710529 0.82 ADORA2A (0.45) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL719983 0.82 L3MBTL1 (0.54) TERTALDH1A1GAAHTTTSHR
SCHEMBL716624 0.82 GAA (0.47) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL714240 0.81 TERT (0.51) NPY5RTERTHPGDALDH1A1GAA
SCHEMBL719451 0.80 DRD4 (0.56) TERTALDH1A1GAATSHRL3MBTL1
SCHEMBL713553 0.79 TERT (0.43) NPY5RTERTHPGDALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US claimed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof TERT, ACIN1, AK2 NPY5R 3892/4885TERT 1/4885HPGD 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.